Molecular Partners (NASDAQ:MOLN - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.11, Zacks reports. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%.
Molecular Partners Stock Down 7.2 %
Shares of NASDAQ MOLN traded down $0.36 during mid-day trading on Monday, hitting $4.65. 9,521 shares of the company were exchanged, compared to its average volume of 4,462. The stock has a 50 day simple moving average of $5.10 and a 200-day simple moving average of $5.36. Molecular Partners has a 1-year low of $3.32 and a 1-year high of $12.70. The firm has a market cap of $187.61 million, a price-to-earnings ratio of -2.15 and a beta of 1.06.
Molecular Partners Company Profile
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Featured Stories
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
